Table 1.
Characteristics of all 14 studies included in the meta-analysis
| Author | Year | Country | Tumor site | N of patients | Age (years) | Gender (M/F) | Cut-off value (mg/dL) | Follow-up (Months) | HR provided from | Outcome | NOS score |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Thurner | 2015 | Austria7 | PCa | 268 | Mean: 66.9±7.5 | 268/0 | 530 | 88(83.3-92.7) | MV/UV | CSS,OS,DFS | 8☆ |
| Wang | 2016 | China34 | PCa | 290 | Mean: 75 (67-79) | 290/0 | 322.5 | 37(24.0-50.3) | MV/UV | CSS,OS,PFS | 6☆ |
| Du | 2013 | China6 | RCC | 286 | Median: 55.72 (28-77) | 185/101 | 300/400 | died: 34.6 survivors: 94.5 | MV/UV | OS,DFS | 7☆ |
| Pichler | 2013 | Austria35 | RCC | 994 | Mean: 63.2±11.9 | 599/395 | 466 | 48.1(0-132) | MV/UV | CSS,OS | 7☆ |
| Erdem | 2014 | Turkey11 | RCC | 156 | Mean: 58.66±11.31 | 91/37 | 343 | 36.5(1-88) | MV/UV | CSS,OS,DFS | 8☆ |
| Niedworok | 2015 | Germany36 | RCC | 98 | Mean: 64.6(18-88) | 61/37 | 281 | 36(20-122) | UV | OS,DFS | 6☆ |
| Sasaki | 2015 | Japan37 | RCC | 126 | Median: 67(37-86) | 84/42 | 399 | 30.8(2-135) | MV/UV | OS | 7☆ |
| Lee | 2016 | Korea10 | RCC | 1511 | Median: 57.6(19-86) | 1077/434 | 328 | 36(24-57) | MV/UV | CSS,OS,PFS | 7☆ |
| Obata | 2016 | Japan38 | RCC | 601 | Median 58(50-67) | 467/134 | 420 | 74(47-107) | MV/UV | CSS,DFS | 8☆ |
| Peng | 2017 | China39 | RCC | 1360 | Median 55(46-65) | 952/408 | 387 | 67(36-74) | MV/UV | CSS,PFS | 7☆ |
| Pichler | 2014 | Austria40 | UTUC | 167 | Mean: 69.3±10.3 | 122/80 | 370 | 28 | MV/UV | CSS,OS | 8☆ |
| Tanaka | 2013 | Japan8 | UTUC | 218 | Mean: 69(38-92) | 160/58 | 450 | 38(3-187) | MV/UV | CSS | 8☆ |
| Zhang | 2016 | China41 | UTUC | 184 | Median: 70(61-75) | 84/100 | 354 | 78(34-92) | MV/UV | CSS,OS | 8☆ |
| Huang | 2016 | China42 | UTUC | 481 | Mean: 65.8±11.1 | 311/170 | 422 | 40(24-64) | MV/UV | CSS,OS | 8☆ |
PCa: prostate cancer, RCC: renal cell carcinoma, UTUC: upper tract urothelial carcinoma, MV: multivariate, UV: univariate, OS: overall survival, CSS: cancer-specific survival, DFS: disease-free survival, PFS: progression-free survival